Evidence map›Paper›PMID 25550804›Full record

ArticleInternational journal of clinical and experimental pathology2014

VEGF/VEGFR2 and PDGF-B/PDGFR-β expression in non-metastatic renal cell carcinoma: a retrospective study in 1,091 consecutive patients.

Sang Hoon Song, In Gab Jeong, Dalsan You, Jun Hyuk Hong, Bumsik Hong, Cheryn Song, Woon Yong Jung, Young Mee Cho, Hanjong Ahn, Choung-Soo Kim

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. NovelJournal of enzyme inhibition and medicinal chemistry · 2023
    Article
  9. Article
  10. Cancer Cell-Derived PDGFB Stimulates mTORC1 Activation in Renal Carcinoma.International journal of molecular sciences · 2023
    Article
  11. Differential expression ofFrontiers in oncology · 2023
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Tumor biology of non-metastatic stages of clear cell renal cell carcinoma; overexpression of stearoyl desaturase-1, EPO/EPO-R system and hypoxia-related proteins.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Sang Hoon SongDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine Pungnap-Dong 388-1, Songpa-Gu, Seoul, Korea.
In Gab JeongDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine Pungnap-Dong 388-1, Songpa-Gu, Seoul, Korea.
Dalsan YouDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine Pungnap-Dong 388-1, Songpa-Gu, Seoul, Korea.
Jun Hyuk HongDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine Pungnap-Dong 388-1, Songpa-Gu, Seoul, Korea.
Bumsik HongDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine Pungnap-Dong 388-1, Songpa-Gu, Seoul, Korea.
Cheryn SongDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine Pungnap-Dong 388-1, Songpa-Gu, Seoul, Korea.
Woon Yong JungDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine Pungnap-Dong 388-1, Songpa-Gu, Seoul, Korea.
Young Mee ChoDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine Pungnap-Dong 388-1, Songpa-Gu, Seoul, Korea.
Hanjong AhnDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine Pungnap-Dong 388-1, Songpa-Gu, Seoul, Korea.
Choung-Soo KimDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine Pungnap-Dong 388-1, Songpa-Gu, Seoul, Korea.
Asan Medical Center · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe aimed to investigate the correlations between the expression of VEGF, PDGF-B, and their receptors (VEGFR2 and PDGFR-β) with pathologic stage or cell type in non-metastatic renal cell carcinoma. MATERIALS AND

methodsVEGF, VEGFR2, PDGF-B, and PDGFR-β protein expression were evaluated immunohistochemically in prospectively collected 1,423 tumour samples obtained during radical or partial nephrectomy at a tertiary referral center. Intensity of expression was quantified on a scale of 0 to 3, and was compared among renal cell carcinoma cell types.

resultsThe study cohort consisted of 1,091 patients, of mean age 54 years, including 968 (88.7%) with clear cell, 82 (7.5%) with papillary, 31 (2.8%) with chromophobe, 4 (0.4%) with unclassified, and 6 (0.5%) with other types of renal cell carcinoma. VEGF expression increased with higher T and N stage and Fuhrman nuclear grade. PDGFR-β expression was highest in clear cell renal cell carcinoma, whereas VEGF and PDGF-B expression were highest in papillary renal cell carcinoma. After adjusting for T stage and Fuhrman nuclear grade using multivariate logistic regression analysis, VEGF (OR = 3.57, P < 0.001), VEGFR2 (OR = 1.82, P = 0.017), and PDGF-B (OR = 2.46, P = 0.019) expression were significantly greater in papillary than in clear cell type.

conclusionsOur results indicate that the cytoplasmic expression of VEGF, VEGFR2, PDGF-B, and PDGFR-β in RCC tumour cells is different in various pathologic stage and cell type. Notably, VEGF and PDGF-B expression are higher in papillary than in clear cell renal cell carcinoma. Further studies using quantitative measurement of proangiogenic factors in tumour cell are needed.

Indexed as

AdultAgedAged, 80 and overCarcinoma, Renal CellFemaleHumansKidney NeoplasmsMaleMiddle AgedPlatelet-Derived Growth FactorReceptor, Platelet-Derived Growth Factor betaRetrospective StudiesVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2Platelet-Derived Growth FactorReceptor, Platelet-Derived Growth Factor betaVascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2Carcinomarenal cellvascular endothelial growth factor Avascular endothelial growth factor receptor-2

Identifiers

PMID25550804
PMCPMC4270555
OpenAlexW1460801345

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.